These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Could concern about climate change increase demand for a Lyme disease vaccine in the U.S.? Motta M Vaccine; 2020 Sep; 38(40):6191-6193. PubMed ID: 32762870 [No Abstract] [Full Text] [Related]
44. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Thompson KM; Tebbens RJ Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390 [TBL] [Abstract][Full Text] [Related]
45. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729 [TBL] [Abstract][Full Text] [Related]
47. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai]. Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120 [TBL] [Abstract][Full Text] [Related]
48. NKT cells join the war on Lyme disease. Godfrey DI; Berzins SP Nat Immunol; 2006 Sep; 7(9):904-6. PubMed ID: 16924252 [No Abstract] [Full Text] [Related]
49. Human health benefits from livestock vaccination for brucellosis: case study. Roth F; Zinsstag J; Orkhon D; Chimed-Ochir G; Hutton G; Cosivi O; Carrin G; Otte J Bull World Health Organ; 2003; 81(12):867-76. PubMed ID: 14997239 [TBL] [Abstract][Full Text] [Related]
50. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Postma MJ; Bos JM; Beutels P; Schilthuis H; van den Hoek JA Vaccine; 2004 May; 22(15-16):1862-7. PubMed ID: 15121296 [TBL] [Abstract][Full Text] [Related]
51. Manufacturer discontinues only Lyme disease vaccine. FDA Consum; 2002; 36(3):5. PubMed ID: 12085815 [No Abstract] [Full Text] [Related]
52. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169 [TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates. Jacobs RJ; Rosenthal P; Meyerhoff AS Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
56. Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic. Hudecková H; Straka S; Szilágyiová M; Avdicová M; Rusnáková S Cent Eur J Public Health; 2002 Dec; 10(4):146-8. PubMed ID: 12528387 [TBL] [Abstract][Full Text] [Related]
57. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. Auwaerter PG; Aucott J; Dumler JS Expert Rev Mol Med; 2004 Jan; 6(2):1-22. PubMed ID: 14987414 [TBL] [Abstract][Full Text] [Related]
58. Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody. Nardelli DT; Burchill MA; England DM; Torrealba J; Callister SM; Schell RF Clin Diagn Lab Immunol; 2004 Nov; 11(6):1075-84. PubMed ID: 15539509 [TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489 [TBL] [Abstract][Full Text] [Related]
60. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Postma MJ; Heijnen ML; Beutels P; Jager JC Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]